Y-Mabs Therapeutics Inc (YMAB) poses a Brand-New Opportunity for Investors with beta value of 0.58
Y-Mabs Therapeutics Inc (NASDAQ: YMAB) established initial surge of 10.31% at $11.88, before settling in for the price of $10.77 at the close. Taking a